Comprehensive Platform for Target Identification and Validation

WuXi Biology’s integrated Advanced Gene Manipulation (AGM™) platform offers innovative technologies and know-how with comprehensive options from cellular, tissue, and in vivo studies.

CRISPR/Cas9 technology

  • Stable or inducible cell line generation (KO,KI, OEX, KD)
  • sgRNA library screen (sgRNAi, sgRNAa)
  • Allele-specific genome editing
  • Genetically engineered mouse models (GEMMs)
  • Primary cells, iPSC gene manipulation
  • Base-editing

CRISPR screening platform

  • In-house pipeline for customized design
  • Cancer cell line based positive selection or negative selection screen to identify mechanism of drug resistance or essential genes
  • CRISPR screen in cancer cell and T cell co-culture to identify regulators of cancer cell response to T cell cytotoxicity
  • Bioinformatics workflow for screening data
  • In vivo CRISPR screen for cancer immunotherapy modulators in syngeneic tumor models

AAV Platform

  • Customized recombinant AAV (rAAV) genome construction and validation
  • General AAV packaging, purification and titering
  • Premade AAV control vectors
  • Large collection of AAV vectors
  • Delivery routes for AAV serotypes


• Inducible KD and OEX